- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Mid-Large Cap Stocks
U.S. Pharmaceuticals & Biotech Mid-Large Cap Stocks
Results
197
Mid-Large Cap Stocks
197 companies
Agios Pharmaceuticals
Market Cap: US$2.2b
A biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States.
AGIO
US$36.61
7D
-3.5%
1Y
-23.8%
Legend Biotech
Market Cap: US$6.1b
Through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
LEGN
US$32.82
7D
-6.7%
1Y
-29.9%
Aurinia Pharmaceuticals
Market Cap: US$1.7b
A biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs.
AUPH
US$12.85
7D
-0.3%
1Y
79.5%
Alvotech
Market Cap: US$2.7b
Through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide.
ALVO
US$8.12
7D
3.8%
1Y
-28.5%
Protagonist Therapeutics
Market Cap: US$4.1b
A biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases.
PTGX
US$64.70
7D
4.1%
1Y
44.0%
Edgewise Therapeutics
Market Cap: US$1.7b
A biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders.
EWTX
US$14.89
7D
-4.2%
1Y
-42.7%
MannKind
Market Cap: US$1.6b
A biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States.
MNKD
US$5.33
7D
-5.0%
1Y
-15.0%
Avadel Pharmaceuticals
Market Cap: US$1.5b
Operates as a biopharmaceutical company in the United States.
AVDL
US$15.33
7D
-5.5%
1Y
21.7%
Natera
Market Cap: US$22.5b
A diagnostics company, provides molecular testing services worldwide.
NTRA
US$163.66
7D
-9.0%
1Y
32.1%
Dyne Therapeutics
Market Cap: US$1.9b
A clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States.
DYN
US$12.58
7D
-9.6%
1Y
-63.7%
Immunovant
Market Cap: US$2.7b
A clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases.
IMVT
US$15.67
7D
1.8%
1Y
-44.6%
Semnur Pharmaceuticals
Market Cap: US$5.6b
Develops and markets non-opioid drugs to treat back pain.
SMNR
US$19.00
7D
57.7%
1Y
64.8%
Apellis Pharmaceuticals
Market Cap: US$2.9b
A commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs.
APLS
US$22.22
7D
-5.0%
1Y
-25.6%
CRISPR Therapeutics
Market Cap: US$5.6b
A gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.
CRSP
US$60.32
7D
-4.2%
1Y
29.7%
AbCellera Biologics
Market Cap: US$1.4b
Engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.
ABCL
US$4.65
7D
-1.5%
1Y
81.6%
Recursion Pharmaceuticals
Market Cap: US$2.1b
Operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States.
RXRX
US$4.63
7D
-6.1%
1Y
-35.4%
Moderna
Market Cap: US$10.1b
A biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally.
MRNA
US$24.61
7D
-3.3%
1Y
-61.5%